Oncolys brings highly experienced management team at Oncolys USA to lead new and innovative programs to the patient.
President and CEO
Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT Pharmaceutical), including Director of R&D Planning. During the time of JT from 1994 to 2004, he launched the innovative HIV drug, Viracept® with Agouron and led many drug development projects such as GVAX project with Cell Genesys and the cancer vaccine project with Corixa. He also, served as clinical project leader mainly for cardiovascular and central nerve system fields at Ono Pharmaceutical Co. He became a member of the Bio Innovation Research Society in 2009.
Mr. Urata became the Executive Officer of Oncolys USA Inc. in 2016. Mr. Urata received his B.Sc. and M.Sc. from Kyoto Pharmaceutical University.
Prior to Oncolys, Mr. Kashihara was a President and CEO of UMN Pharma Inc. and successfully managed rapid business growth during the start-up period, during which UMN Pharma raised a total of $30M. Prior to that, he was a manager of licensing at Santen Pharmaceutical Co., Ltd., after serving as a pharmacological researcher at Ciba-Geigy Japan Limited (Novartis Pharma K.K.).
Mr. Kashihara became a President of Oncolys USA Inc. in 2016. He also serves as Vice President of Business Development at Oncolys BioPharma Inc., interim CEO of Liquid Biotech USA Inc., and board member of Precision Virologics Inc. Mr. Kashihara received his B.Sc. and M.Sc. from Kyoto Pharmaceutical University and M.B.A. from Trinity College Dublin in Republic of Ireland.
Talia BiranVP, Clinical Development &
Prior to Oncolys, Talia played a pivotal role at Lexicon Pharmaceuticals as Executive Director, where she established the US medical affairs infrastructure for Oncology and Diabetes programs and led the development and launch of Lexicon's first drug candidate, Telotristat Ethyl ( Xermelo, ® Carcinoid Syndrome Diarrhea) (Licensed Ex-US to Ipsen Inc)
Talia holds a Master of Science (M.Sc) in Microbiology from Tel-Aviv University, Department of Life Sciences, in Tel-Aviv, Israel. Her thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of SV-40 and its link to tumorigenesis.